Overview

Also known as:

Clinical phenotype terms— hover any for plain English:

Sinus tachycardiaHP:0011703Thyrotoxicosis with diffuse goiterHP:0011784Increased circulating T4 concentrationHP:0031506Graves diseaseHP:0100647Small anterior fontanelleHP:0000237

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event

Sep 2014

HUMIRA: FDA approved

Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Remicade

infliximab· Janssen Biotech, Inc.■ Boxed Warning

reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate respons…

reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy

View Details →FDA Label ↗

HUMIRA

adalimumab· AbbVie, Inc.■ Boxed WarningOrphan Drug

Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response …

Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

View Details →FDA Label ↗